Ilya Pharma strengthens board with appointments of corporate development specialist Hughes Crameri and Galderma veteran Carson
Uppsala, May 3, 2022: Ilya Pharma (the Company), a clinical stage immunotherapy company today announced the appointments of Dr Melya Hughes Crameri and William (Bill) Carson to the Board of Directors. The appointments come as the company approaches key stages in the development of its portfolio of three first-in-class immunotherapies for skin and mucosal diseases - ILP100-Topical for treatment of surgical wounds in diabetic, pre-diabetic and obese patients especially at risk, ILP100-Topical for diabetic ulcers and ILP100-Oral for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors.
Melya Hughes Crameri, PhD is a seasoned life sciences entrepreneur with over 25 years’ experience in the biotech and pharmaceutical industry, in Europe as well as in the US. Early in her career she worked in patent law (US Patent Bar and European Patent Attorney), and over recent years she has engaged in business development, diligence, fundraising, partnering and strategy development for a variety of life science and pharmaceutical companies. She was responsible for all licensing and patents at Novartis Research Foundation (FMI) globally for 5 years, and as an early executive team member of Evolva SA, raising> Euros 60M in financing, built up Evolva’s US operations in Palo Alto, California, as founder and CEO.
Bill Carson has held senior leadership roles at Novartis, Bayer and Galderma in Manufacturing, Product Development and Regulatory Affairs. He has extensive experience of M&A in its various forms as well as integration of projects and operations after the M&A transactions. Backed by knowledge of evaluating portfolios with clinical programs, valuation of clinical programs, commercialization, and market introduction of pharmaceuticals. Bill has also led acquisition processes and built up multiple contract manufacturing organizations for pharmaceuticals and medical devices.
Ilya Pharma CEO and Co-Founder Evelina Vågesjö adds: “I am delighted to welcome Melya and Bill to the Board and look forward to working with them in developing the company and our exciting portfolio of products. We now definitely have a diverse Board of Directors with knowledge, networks and relevant experience for exactly what the company should deliver in the coming three years. The diversity is also reflected in the gender, age and geographic coverage”.
Notes to editors
About Ilya Pharma - Ilya Pharma is a clinical stage biopharma company, developing novel drug candidates from its proprietary technology platform to clinical proof of concept in relevant patient groups with identified unmet medical needs. The company has recently reached multiple key milestones in the development of its portfolio of three first-in-class immunotherapies for skin and mucosal diseases - ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic ulcers and ILP100-Oral for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors (ICIC) and inflammatory bowel disease (IBD).
The lead drug candidate ILP100 is also known as emilomogene sigulactibac as recommended by the WHO.
For more information, please contact:
Evelina Vågesjö, CEO Tel: +46 (0) 70 636 64 94
Email: evelina.vagesjo@ilyapharma.se
Media
RHApr - Richard Hayhurst Tel: +44 (0) 7711 821527
